Aurobindo Pharma Share Price
₹1,241.70 -13 (-1.04%)
21 Dec, 2024 17:02
Start SIP in AUROPHARMA
Start SIPPerformance
- Low
- ₹1,236
- High
- ₹1,275
- 52 Week Low
- ₹959
- 52 Week High
- ₹1,592
- Open Price₹1,255
- Previous Close₹1,255
- Volume1,843,118
Investment Returns
- Over 1 Month -0.67%
- Over 3 Month -17.02%
- Over 6 Month -0.12%
- Over 1 Year + 20.23%
Smart Investing Starts Here Start SIP with Aurobindo Pharma for Steady Growth!
Aurobindo Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 20.1
- PEG Ratio
- 0.4
- Market Cap Cr
- 72,118
- P/B Ratio
- 2.4
- Average True Range
- 34.16
- EPS
- 62.24
- Dividend Yield
- 0.1
- MACD Signal
- -29.46
- RSI
- 44.58
- MFI
- 42.84
Aurobindo Pharma Financials
Aurobindo Pharma Technicals
EMA & SMA
- Bullish Moving Average 6
- Bearish Moving Average 10
- 20 Day
- ₹1,249.32
- 50 Day
- ₹1,306.46
- 100 Day
- ₹1,335.35
- 200 Day
- ₹1,279.77
Resistance and Support
- R3 1,305.70
- R2 1,290.50
- R1 1,266.10
- S1 1,226.50
- S2 1,211.30
- S3 1,186.90
Aurobindo Pharma Corporate Actions - Bonus, Splits, Dividends
Aurobindo Pharma F&O
About Aurobindo Pharma
- NSE Symbol
- AUROPHARMA
- BSE Symbol
- 524804
- ISIN
- INE406A01037
Similar Stocks to Aurobindo Pharma
Aurobindo Pharma FAQs
Aurobindo Pharma share price is ₹1,241 As on 21 December, 2024 | 16:48
The Market Cap of Aurobindo Pharma is ₹72118.1 Cr As on 21 December, 2024 | 16:48
The P/E ratio of Aurobindo Pharma is 20.1 As on 21 December, 2024 | 16:48
The PB ratio of Aurobindo Pharma is 2.4 As on 21 December, 2024 | 16:48
Aurobindo Pharma has an operating revenue of Rs.24,010.31 Cr. on a trailing 12-month basis. An annual revenue growth of 8% is good, Pre-tax margin of 30% is great. Many brokers and analysts have recommended 'Buy' on the stock.
Aurobindo Pharma Ltd. has declared 40 dividends since May 10, 2000.
The stock price CAGR of Aurobindo Pharma for 10 Years is 30%, 5 Years is 0%, 3 Years is -3%, 1 Year is -25%.
Aurobindo Pharma has an ROE of 24% which is exceptional.
Aurobindo Pharma has a reasonable debt to equity of 1%, which signals a healthy balance sheet.
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.